help button home button ClinMed NetPrints
Warning: This article has not yet been accepted for publication by a peer reviewed journal. It is presented here mainly for the benefit of fellow researchers. Casual readers should not act on its findings, and journalists should be wary of reporting them.

This Article
Right arrow Full Text
Right arrow Similar articles in this netprints
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marshall, T. G
Right arrow Articles by Marshall, F. E
Right arrow Search for Related Content
Right arrow Articles by Marshall, T. G
Right arrow Articles by Marshall, F. E
Related Collections
Right arrow CLINICAL:
Molecular Medicine

Right arrow Rheumatology:
Other Rheumatology

Right arrow CLINICAL:

clinmed/2003010001v1 (January 27, 2003)
Contact author(s) for copyright information

New Treatments Emerge as Sarcoidosis Yields Up its Secrets

Trevor G Marshall, and Frances E Marshall

Background: Sarcoidosis is a hyper-inflammatory disorder of uncertain etiology. The objective of this study was to identify patients who were reporting hypersensitivities to sunlight, and investigate whether this trait might help to identify the etiology of sarcoid inflammation. Results: After studying patients who were able to control their Sarcoidosis symptoms simply by limiting their exposure to sunlight, and others who were benefiting from Angiotensin Receptor Blockade, we identified, and confirmed, a working hypothesis detailing each step of the molecular chemistry leading to the inflammation seen in Sarcoidosis. The study also identified, and validated, a number of novel treatments. Discussion: We found that the secosteroid hormone 1,25-dihydroxyvitamin D (1,25-D) clearly plays an important part in the etiology and symptomology of Sarcoidosis, regardless of the calcemic state of the patient. We described an inflammatory biochemistry which identified 1,25-D and Angiotensin II as the key hormonal mediators. Many patientsí symptoms were eased when the concentration of the metabolite 25-hydroxyvitamin D (25-D) was reduced by isolation from sunlight, and the removal of all sources of Vitamin D from the diet. 25-D provides fuel for the unregulated extra-renal production of the secosteroid. This novel therapy also improved markers of disease activity, such as Angiotensin Converting Enzyme, and Alkaline Phosphatase, at the same time that the 1,25-D levels were being normalized. The D-Ratio, serum 1,25-D (pg/ml) divided by 25-D (ng/ml), gives an indication of the amount of nonrenal 1,25-D being produced within the granulomatous inflammation. It can be used to monitor a patientís response to therapy. Angiotensin II plays a vital role in the inflammatory cycle, and a novel form of Angiotensin Receptor Blockade was confirmed as a probable therapeutic alternative to the use of systemic corticosteroids.

Rapid responses to this article:

Read all Rapid responses

A Fresh Approach To This Disease
Evelin G. Lindner
ClinMed NetPrints, 1 Apr 2003 [Full text]
Angiotensin Receptor Blockers Are Worthy of Close Consideration
Meg M. Mangin, RN
ClinMed NetPrints, 1 Apr 2003 [Full text]
Expanded research needed
Leonard E. Toon
ClinMed NetPrints, 1 Apr 2003 [Full text]